24 results
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
of our securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
their efforts and commitment, and we wish them continued success in their individual paths forward. Our reprioritization is expected to decrease
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
of Allowance demonstrates our commitment to protecting Allocetra’s™ commercial opportunities in key geographies around the world. It also highlights
6-K
EX-99.1
ommq4wurps7h
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
FWP
fc9dznwgpt9xo5z
10 Feb 21
Free writing prospectus
6:08am
FWP
xxl2bfuuz3mlhfv62
9 Feb 21
Free writing prospectus
5:21pm
6-K
EX-10.1
3a8fr xa0
22 Oct 20
Report of Foreign Private Issuer
8:47am
6-K
EX-99.1
6ijw2vn l9fpdxgltym
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
424B5
ouo02qxz1ss
3 Mar 20
Prospectus supplement for primary offering
5:13pm
424B5
0ivuvyg z3cuj7
26 Feb 20
Prospectus supplement for primary offering
8:23am
6-K
EX-99.2
o0eqf61m
27 Mar 19
Securities Purchase Agreement
8:32am
6-K
EX-99.2
gwb1g im9ko
6 Dec 18
Amended Notice of Annual and Extraordinary General Meeting of the Shareholders
4:43pm
6-K
EX-99.1
vpgdz1dqqb140v19qyz
19 Nov 18
Agreement and Plan of Merger
4:34pm